Opdivo And Eliquis Carry Bristol’s Q1; Company Continues To Defend IO Strategy
Executive Summary
Novel oral anticoagulant Eliquis (apixaban) brought in $1.5bn in the first quarter and is set to overtake warfarin later this year. But Bristol remains on the defense on IO after a disappointing AACR.
You may also be interested in...
Novartis' Growth Driver Tafinlar/Mekinist Picks Up New Melanoma, Thyroid Indications
New FDA labeling brings Tafinlar/Mekinist into adjuvant melanoma setting, but Bristol's competing Opdivo already has captured nearly 50% of the market and is approved regardless of genetic mutation.
Merck Files Keytruda/Chemo Combo Early With FDA In 1L Squamous Lung Cancer
Also, Bristol has filed its Opdivo/Yervoy IO combination in Europe for first-line NSCLC, including squamous and non-squamous disease, based on CheckMate 227 data; some analysts expect FDA will accept the same dataset.
Merck's Keytruda Keeps Nipping At Opdivo's Heels
In the US there are more new starts on Keytruda than any other immunotherapy, Merck says in first-quarter earnings report.